Layoff season continues

Share this article:

Layoffs abound.

The fourth-quarter layoff tradition continues. Below, a mini roundup:

Actavis is laying off 30% of its sales staff, having assessed post-Warner Chilcott needs. The deal closed Oct. 1, and Actavis said 350 employees drawn from its sales force, district managers, account managers and management are losing their jobs.

Bayer is releasing 50 employees. Pharmalot found the news in a California filing about the closure of a Sunnyvale, CA, plant associated with its discontinued diabetes monitors A1CNow and A1CNowSelfCheck.

These layoffs come on top of other reorganizations, such as Shire's R&D cuts in Basingstoke, UK; Novartis's pink slipping of California-based researchers; and Merck's layoff of 8,500 workers.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.